BiotechTube

placebo + valdecoxib + valdecoxib

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Laparoscopic Cholecystectomy

Conditions

Laparoscopic Cholecystectomy, Pain

Trial Timeline

Nov 1, 2002 → Jul 1, 2003

NCT ID
NCT00661635

About placebo + valdecoxib + valdecoxib

placebo + valdecoxib + valdecoxib is a phase 3 stage product being developed by Pfizer for Laparoscopic Cholecystectomy. The current trial status is completed. This product is registered under clinical trial identifier NCT00661635. Target conditions include Laparoscopic Cholecystectomy, Pain.

What happened to similar drugs?

3 of 5 similar drugs in Laparoscopic Cholecystectomy were approved

Approved (3) Terminated (1) Active (1)
✅Rocuronium + RocuroniumMerckApproved
✅Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
✅etoricoxib 120 mgMerckApproved
🔄SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
❌N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00650039Phase 3Completed
NCT00661635Phase 3Completed

Competing Products

7 competing products in Laparoscopic Cholecystectomy

See all competitors
ProductCompanyStageHype Score
Pudexacianinium chlorideAstellas PharmaPhase 2
35
SHR0410 Injection + SHR0410 Injection + PlaceboJiangsu Hengrui MedicinePhase 3
36
Entereg + Entereg + placeboMerckPhase 2
35
Rocuronium + RocuroniumMerckApproved
43
Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2MerckApproved
39
etoricoxib 120 mgMerckApproved
43
N1539 + N1539 + N1539 + Ketorolac Tromethamine + PlaceboAlkermesPhase 3
29